Open AccessCurrent opportunities for the treatment of respiratory diseases in paediatric practice
Author(s) -
В. Н. Дроздов,
Н. Ю. Сереброва,
О. А. Воробьева,
А. К. Стародубцев,
О. В. Добровольский
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-17-132-136
Subject(s) - medicine , salbutamol , intensive care medicine , cystic fibrosis , asthma , primary ciliary dyskinesia , pneumonia , respiratory system , drug , adverse effect , pharmacotherapy , immunology , bronchiectasis , pharmacology , lung
Immediacy of the problem of combination therapy of respiratory diseases in paediatric practice is caused by their multifactorial pathogenesis in children and the need to achieve a high clinical effect in the use of drugs at relatively low doses and with minimum risks of serious adverse effects and drug interactions. The fixed-dose combination of salbutamol, bromhexine and guaifenesin produced in the form of tablets and syrup fully meets these requirements, which makes it possible to use it in children and adults with acute, chronic infectious (ARVI, bacterial pneumonia, respiratory tuberculosis, etc.) and non-infectious (bronchial asthma, pulmonary cystic fibrosis, primary ciliary dyskinesia, etc.) diseases.